Bioxytran (Bioxytran) Debt-to-Equity : -3.29 (As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Bioxytran Debt-to-Equity?

Bioxytran's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.97 Mil. Bioxytran's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Bioxytran's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $-0.30 Mil. Bioxytran's debt to equity for the quarter that ended in Mar. 2024 was -3.29.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Bioxytran's Debt-to-Equity or its related term are showing as below:

BIXT' s Debt-to-Equity Range Over the Past 10 Years
Min: -10.46 Med: -0.77 Max: 0.21
Current: -3.29

During the past 13 years, the highest Debt-to-Equity Ratio of Bioxytran was 0.21. The lowest was -10.46. And the median was -0.77.

BIXT's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs BIXT: -3.29

Bioxytran Debt-to-Equity Historical Data

The historical data trend for Bioxytran's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioxytran Debt-to-Equity Chart

Bioxytran Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-1.07

-0.57

-0.77

-0.80

-0.79

Bioxytran Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															-0.63	-1.00	-1.30	-0.79	-3.29

Competitive Comparison of Bioxytran's Debt-to-Equity

For the Biotechnology subindustry, Bioxytran's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bioxytran's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioxytran's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Bioxytran's Debt-to-Equity falls into.

Bioxytran Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Bioxytran's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.925	+	0)	/	-2.431
	=	-0.79

Bioxytran's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.973	+	0)	/	-0.296
	=	-3.29

Bioxytran (OTCPK:BIXT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Bioxytran Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Bioxytran's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioxytran (Bioxytran) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioxytran Inc (OTCPK:BIXT) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

75 2nd Avenue, Suite 605, Needham, MA, USA, 02494

Website

https://www.bioxytraninc.com

Bioxytran Inc is a biopharmaceutical company. The company is engaged in developing anti-necrosis drugs that treat a variety of medical conditions resulting from Ischemia. It is also focusing on the development and commercialization of treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke. Its product candidate, BXT-25, is an anti-necrosis drug that carries oxygen to tissues when the flow of blood is blocked. Its other drug candidate BXT-252 is a resuscitative agent in a variety of wound healing applications.

Executives

Dale H Conaway	director	189 WELLS AVE, NEWTON MA 02459
Alan M Hoberman	director	6134 MECHANICSVILLE ROAD, PO BOX 56, MECHANICSVILLE PA 18934
Anders Utter	director	BIOXYTRAN, INC, 233 NEEDHAM ST., SUITE 300, NEWTON MA 02464
David Platt	director, 10 percent owner, officer: CEO	12 APPLETON CIRCLE, NEWTON MA 02459
Hana Chen-walden	director	7 RUE ARISTIDE MAILLOL, PARIS I0 75015
Michael Sheikh	officer: Chief Communication Officer	1905 S AUDUBON CT, SPOKANE WA 99224
Binder Offer	other: No longer 10% owner	PASQUALE VIA SETTEMBRIMI 14A, SAN MARIANO 06073, CORCIANO PG ITALY L6 00000
Ola Soderquist	10 percent owner, officer: CFO	47 HAMMOND STREET, UNIT 2, WALTHAM MA 02451
Lawrence W. Bonafide	director	78365 HWY 111, SUITE 287, LA QUINTA CA 92253
Nathan Marks	director	78365 HWY 111, SUITE 287, LA QUINTA CA 92253
Dave Quincy Farber	director, officer: President	78365 HWY 111, SUITE 287, LA QUINTA CA 92253
David Lee	director	78365 HWY 111, SUITE 287, LA QUINTA CA 92253
Donita R. Kendig	director, officer: Secretary/Treasurer	78365 HWY 11, SUITE 287, LA QUINTA CA 92253
Afcc, Llc	10 percent owner	1621 CENTRAL AVENUE, CHEYENNE WY 82001
Paul W Hai	10 percent owner	20443 TIMBERLINE, BEND OR 97701